Insights into Hepatocellular Carcinoma (HCC) 2020 (Midwest)
Current treatment practice attitudes toward therapy of unresectable advanced hepatocellular carcinoma (HCC), recently introduced and upcoming agents
Midwest – November 4, 2020
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Scottsdale, Az
REPORT SNAPSHOT
- A roundtable discussion moderated by an Axess Oncology Network physician focusing on treatment of HCC was held on November 4, 2020, in a virtual setting
- Disease state and data presentations were developed in conjunction with Tanios Bekaii-Saab, MD, a medical expert from the Mayo Clinic in Phoenix, Arizona
- The group of advisors comprised 12 community oncologists from the midwest United States
- Insights on the following therapies were obtained: sorafenib vs lenvatinib; checkpoint inhibitors including atezolizumab and nivolumab; cabozantinib, nivolumab vs pembrolizumab, ramucirumab (high alpha-fetoprotein [AFP]), regorafenib, ipilimumab + nivolumab
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system (ARS) questioning and moderated discussion
- Attendees of the roundtable represented community oncologists from Illinois, Michigan, Ohio, and Indiana
